Table 2.
Genetic Variants | Seattle Cohort | PROGRESS Cohort | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
SNP | Chr. | Gene | Alleles1 | MAF2 | HR | 95% CI | Model3 | MAF2 | HR | 95% CI | P-value4 | Model |
rs1137100 | 1p31 | LEPR | A/G | 0.27 | 0.29 | 0.14–0.60 | Dom: ACP | 0.26 | 1.65 | 1.08–2.51 | NC | Dom: ACP |
rs228697 | 1p36 | PER3 | C/G | 0.11 | 0.25 | 0.10–0.60 | Dom: ACP | 0.10 | 1.39 | 0.84–2.30 | NC | Dom: ACP |
rs635261 | 1q25 | RNASEL | G/C | 0.36 | 0.22 | 0.07–0.65 | Rec: ACP | 0.39 | 0.35 | 0.18–0.66 | 0.002 | Rec: ACP |
rs627839 | 1q25 | RNASEL | G/T | 0.47 | 3.98 | 1.64–9.65 | Dom: ACP | 0.48 | 0.83 | 0.56–1.21 | NC | Dom: ACP |
rs4583514 | 2p21 | MSH2 | G/A | 0.38 | 2.49 | 1.21–5.10 | Dom: ACP | 0.38 | 0.68 | 0.45–1.03 | NC | Dom: ACP |
rs4608577 | 2p21 | MSH2 | T/G | 0.17 | 2.04 | 1.36–3.07 | Tre: A | 0.17 | 1.09 | 0.77–1.55 | 0.33 | Tre: ACP |
rs523349 | 2p23 | SRD5A2 | C/G | 0.29 | 0.49 | 0.28–0.86 | Dom: A | 0.29 | 1.08 | 0.71–1.67 | NC | Dom: ACP |
rs12467911 | 2p23 | SRD5A2 | C/T | 0.28 | 0.45 | 0.24–0.81 | Dom: A | 0.30 | 1.14 | 0.75–1.72 | NC | Dom: ACP |
rs11710277 | 3p21 | SEMA3F | A/G | 0.09 | 3.71 | 1.75–7.90 | Dom: ACP | 0.06 | 0.75 | 0.39–1.42 | NC | Dom: ACP |
rs11205 | 5p23 | HSD17B4 | A/G | 0.39 | 0.21 | 0.06–0.70 | Rec: ACP | 0.43 | 1.21 | 0.79–1.86 | NC | Rec: A |
rs2070874 | 5q31 | IL4 | C/T | 0.16 | 2.16 | 1.27–3.67 | Dom: A | 0.16 | 1.17 | 0.80–1.72 | 0.25 | Dom: A |
rs1799964 | 6p21 | TNF/LTA | T/C | 0.21 | 0.39 | 0.20–0.77 | Dom: A | 0.22 | 1.19 | 0.82–1.72 | NC | Dom: A |
rs4645959 | 8q24 | C-MYC | A/G | 0.04 | 0 | 0.00–inf. | Tre: ACP | 0.04 | 1.14 | 0.56–2.32 | NC | Tre: ACP |
rs1029153 | 10q11 | CXCL12 | T/C | 0.31 | 0.22 | 0.07–0.75 | Tre: A | 0.29 | 1.14 | 0.87–1.51 | NC | Tre: A |
rs2839685 | 10q11 | CXCL12 | C/T | 0.15 | 28.2 | 7.21–110.2 | Rec: ACP | 0.14 | 0.58 | 0.11–3.10 | NC | Rec: A |
rs2308327 | 10q26 | MGMT | A/G | 0.13 | 0.32 | 0.13–0.78 | Tre: A | 0.11 | 0.85 | 0.55–1.31 | 0.26 | Tre: ACP |
rs10778534 | 12q23 | CRY1 | T/C | 0.36 | 2.21 | 1.19–4.12 | Dom: A | 0.36 | 0.68 | 0.45–1.03 | NC | Dom: ACP |
rs2494750 | 14q32 | AKT1 | C/G | 0.07 | 0.22 | 0.07–0.70 | Tre: ACP | 0.05 | 0.45 | 0.23–0.90 | 0.016 | Tre: A |
rs1799814 | 15q24 | CYP1A1 | C/A | 0.05 | 0.13 | 0.03–0.57 | Tre: ACP | 0.05 | 1.27 | 0.61–2.64 | NC | Tre: ACP |
rs25487 | 19q13 | XRCC1 | G/A | 0.36 | 0.49 | 0.31–0.77 | Tre: A | 0.37 | 0.85 | 0.65–1.12 | 0.17 | Tre: A |
rs915927 | 19q13 | XRCC1 | A/G | 0.43 | 2.54 | 1.24–5.18 | Dom: A | 0.41 | 1.91 | 1.21–3.02 | 0.009 | Dom: ACP |
rs5993891 | 22q11 | ARVCF | C/T | 0.05 | 0.21 | 0.07–0.61 | Dom: ACP | 0.05 | 1.53 | 0.91–2.57 | NC | Dom: A |
Major/minor allele.
MAF: minor allele frequency, calculated from cases who did not die of prostate cancer.
Model: Dom= dominant, Rec= recessive, Tre= trend; A= age at diagnosis, ACP= age plus clinicopathological covariates (i.e., Gleason score, diagnostic PSA, stage, and primary treatment).
NC: not confirmed (i.e., the direction of the HR in the PROGRESS confirmation cohort was in the opposite direction compared to the HR in the Seattle discovery cohort).